Add to ORKGInterpretation of genotypic resistance to ritonavir-boosted saquinavir (SQV/r) is still incomplete due to limited data correlating genotypes with virological response to SQV/r. We extracted baseline VL and genotypes as well as 3-month virological outcome of HIV+ patientsenrolled in Argenta, GART, Havana and a prospective cohort (INMI), undergoing SQV/r-containing salvage regimens. Single mutations found with an association of p<0.2 respect to the 3-month VL log change from baseline (3m delta) by multiple linear regression, after adjusting by ritonavir dose, were given a weighted score according to the correlation coefficient. A technique using geneticalgorithms and fuzzy operators was tested in parallel on the whole patients set to find the...
Background: There is not yet consensus on interpretation of genotypic HIV-1 resistance to darunavir ...
The objective of this study was to improve the prediction of the impact of HIV-1 protease mutations ...
International audienceBACKGROUND: Different approaches using genotypic, pharmacokinetic parameters o...
Use of human immunode®ciency virus (HIV) drug-resistance testing in therapeutic decision making may ...
Use of human immunode®ciency virus (HIV) drug-resistance testing in therapeutic decision making may ...
Background: Tests for resistance to HIV drugs are avail-able for clinical use; however, their predic...
OBJECTIVES: The protease inhibitor atazanavir (ATV) can be used either boosted by ritonavir (ATV300...
BACKGROUND: There are few data on the selection of resistance by ritonavir-boosted saquinavir (SQV/r...
Several genotypic interpretation scores have been proposed for the evaluation of susceptibility to l...
BACKGROUND: Inferring response to antiretroviral therapy from the viral genotype alone is challengi...
Tipranavir, a non-peptidic protease inhibitor which shows in vitro efficacy against some HIV-1-resis...
OBJECTIVES: The objective of this study was to improve the prediction of the impact of HIV-1 protea...
International audienceObjectives: To determine how the load of rilpivirine-resistant variants (mutat...
Objectives: To compare three methods for using HIV-1 genotype to predict antiretroviral drug suscept...
BACKGROUND: There is not yet consensus on interpretation of genotypic HIV-1 resistance to darunavir ...
Background: There is not yet consensus on interpretation of genotypic HIV-1 resistance to darunavir ...
The objective of this study was to improve the prediction of the impact of HIV-1 protease mutations ...
International audienceBACKGROUND: Different approaches using genotypic, pharmacokinetic parameters o...
Use of human immunode®ciency virus (HIV) drug-resistance testing in therapeutic decision making may ...
Use of human immunode®ciency virus (HIV) drug-resistance testing in therapeutic decision making may ...
Background: Tests for resistance to HIV drugs are avail-able for clinical use; however, their predic...
OBJECTIVES: The protease inhibitor atazanavir (ATV) can be used either boosted by ritonavir (ATV300...
BACKGROUND: There are few data on the selection of resistance by ritonavir-boosted saquinavir (SQV/r...
Several genotypic interpretation scores have been proposed for the evaluation of susceptibility to l...
BACKGROUND: Inferring response to antiretroviral therapy from the viral genotype alone is challengi...
Tipranavir, a non-peptidic protease inhibitor which shows in vitro efficacy against some HIV-1-resis...
OBJECTIVES: The objective of this study was to improve the prediction of the impact of HIV-1 protea...
International audienceObjectives: To determine how the load of rilpivirine-resistant variants (mutat...
Objectives: To compare three methods for using HIV-1 genotype to predict antiretroviral drug suscept...
BACKGROUND: There is not yet consensus on interpretation of genotypic HIV-1 resistance to darunavir ...
Background: There is not yet consensus on interpretation of genotypic HIV-1 resistance to darunavir ...
The objective of this study was to improve the prediction of the impact of HIV-1 protease mutations ...
International audienceBACKGROUND: Different approaches using genotypic, pharmacokinetic parameters o...